NICE panel hears appeals on kidney cancer drugs
This article was originally published in Scrip
Executive Summary
The UK's National Institute for health and Clinical Excellence heard appeals this week against its rejection of several drugs for treating advanced and/or metastatic renal cell carcinoma on cost-effectiveness grounds.